Privately-held BridGene Biosciences has announced a strategic collaboration and licensing agreement with Japan’s Takeda. The ...
SAN JOSE, CA, USA I5, 2025 I BridGene Biosciences, Inc., a leader in the discovery of small molecule drugs for traditionally “hard-to-drug” targets, announced today a strategic collaboration and ...
Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology. Takeda will pay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback